209 related articles for article (PubMed ID: 25123655)
1. Role of somatic cancer mutations in human protein lysine methyltransferases.
Kudithipudi S; Jeltsch A
Biochim Biophys Acta; 2014 Dec; 1846(2):366-79. PubMed ID: 25123655
[TBL] [Abstract][Full Text] [Related]
2. Approaching the catalytic mechanism of protein lysine methyltransferases by biochemical and simulation techniques.
Schnee P; Pleiss J; Jeltsch A
Crit Rev Biochem Mol Biol; 2024; 59(1-2):20-68. PubMed ID: 38449437
[TBL] [Abstract][Full Text] [Related]
3. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Chopra M; Bohlander SK
Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein lysine methylation and demethylation in cancers.
He Y; Korboukh I; Jin J; Huang J
Acta Biochim Biophys Sin (Shanghai); 2012 Jan; 44(1):70-9. PubMed ID: 22194015
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of histone methylation catalyzed by protein lysine methyltransferase SET7/9 and origin of product specificity.
Guo HB; Guo H
Proc Natl Acad Sci U S A; 2007 May; 104(21):8797-802. PubMed ID: 17517655
[TBL] [Abstract][Full Text] [Related]
6. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
[TBL] [Abstract][Full Text] [Related]
8. The T1150A cancer mutant of the protein lysine dimethyltransferase NSD2 can introduce H3K36 trimethylation.
Khella MS; Schnee P; Weirich S; Bui T; Bröhm A; Bashtrykov P; Pleiss J; Jeltsch A
J Biol Chem; 2023 Jun; 299(6):104796. PubMed ID: 37150325
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of protein lysine methyltransferases in cancer.
Vougiouklakis T; Bernard BJ; Nigam N; Burkitt K; Nakamura Y; Saloura V
Clin Epigenetics; 2020 Oct; 12(1):146. PubMed ID: 33050946
[TBL] [Abstract][Full Text] [Related]
10. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
11. The NSD1 and EZH2 overgrowth genes, similarities and differences.
Tatton-Brown K; Rahman N
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):86-91. PubMed ID: 23592277
[TBL] [Abstract][Full Text] [Related]
12. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
13. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
14. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
16. Protein Lysine Methyltransferases Inhibitors.
Li Y; Ding L; Ren S; Zhang W; Rao GW
Curr Med Chem; 2023; 30(27):3060-3089. PubMed ID: 36043747
[TBL] [Abstract][Full Text] [Related]
17. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
18. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
20. Somatic Cancer Mutations in the SUV420H1 Protein Lysine Methyltransferase Modulate Its Catalytic Activity.
Bröhm A; Elsawy H; Rathert P; Kudithipudi S; Schoch T; Schuhmacher MK; Weirich S; Jeltsch A
J Mol Biol; 2019 Aug; 431(17):3068-3080. PubMed ID: 31255706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
